Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Ju.com "Second Round Meme Launchpad" Phase 7 CLOSE raises over 990 millions USD, scheduled to go live at 8 PM tonight

Ju.com "Second Round Meme Launchpad" Phase 7 CLOSE raises over 990 millions USD, scheduled to go live at 8 PM tonight

ChaincatcherChaincatcher2026/04/20 08:19
Show original

According to ChainCatcher, the subscription for the 7th project CLOSE ended on April 20 at 16:00, and the TGE will be completed on April 20 at 20:00. Over 51,000 people participated in this event, with a total subscription amount of 99,082,862 USDT. After settlement, there will be no lock-up for this round of CLOSE subscription assets; the tokens will be credited as spot assets, allowing users to sell or withdraw immediately.

This round continued the multi-currency participation mechanism, allowing users to subscribe with JU / USDT / BTC / ETH, with the platform allocating uniformly based on USDT value. A dynamic success rate model was introduced for this round, where the success rate increases by 0.2% for every 5 million USDT raised. Successfully inviting friends to participate allows users to share up to 20% of the final token issuance as a reward.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.